Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients
- PMID: 35319153
- DOI: 10.1111/ddg.14675
Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical